Telomerase as a therapeutic target in cancer

Ginelle C. Gellert; Shalmica R. Jackson; Z. Gunnur Dikmen; Woodring E. Wright; Jerry W. Shay

doi:10.1016/j.ddmec.2005.05.009

Telomerase as a therapeutic target in cancer

Ginelle C. Gellert, Shalmica R. Jackson, Z. Gunnur Dikmen, Woodring E. Wright, Jerry W. Shay

Research output: Contribution to journal › Review article › peer-review

27 Scopus citations

Abstract

Advances in chromosome dynamics have increased our understanding of the significant role of telomeres and telomerase in cancer. Telomerase is expressed in almost all cancer cells but is inactive in most normal somatic cells. Therefore, telomerase is an important target for the design of therapeutic agents that might have minimal side effects. Herein, we evaluate current approaches to telomerase-targeted therapy, discuss the benefits and disadvantages, and speculate on the future direction of telomerase inhibitors as cancer therapeutics.

Original language	English (US)
Pages (from-to)	159-164
Number of pages	6
Journal	Drug Discovery Today: Disease Mechanisms
Volume	2
Issue number	2
DOIs	https://doi.org/10.1016/j.ddmec.2005.05.009
State	Published - 2005

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery

Access to Document

10.1016/j.ddmec.2005.05.009

Cite this

@article{88cf2586ac534fe7a1832e3094fe1016,

title = "Telomerase as a therapeutic target in cancer",

abstract = "Advances in chromosome dynamics have increased our understanding of the significant role of telomeres and telomerase in cancer. Telomerase is expressed in almost all cancer cells but is inactive in most normal somatic cells. Therefore, telomerase is an important target for the design of therapeutic agents that might have minimal side effects. Herein, we evaluate current approaches to telomerase-targeted therapy, discuss the benefits and disadvantages, and speculate on the future direction of telomerase inhibitors as cancer therapeutics.",

author = "Gellert, {Ginelle C.} and Jackson, {Shalmica R.} and Dikmen, {Z. Gunnur} and Wright, {Woodring E.} and Shay, {Jerry W.}",

note = "Funding Information: This work was supported by Lung SPORE CA70907 and the Nash Foundation. We thank Stanton Fernald for the illustrations.",

year = "2005",

doi = "10.1016/j.ddmec.2005.05.009",

language = "English (US)",

volume = "2",

pages = "159--164",

journal = "Drug Discovery Today: Disease Mechanisms",

issn = "1740-6765",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Telomerase as a therapeutic target in cancer

AU - Gellert, Ginelle C.

AU - Jackson, Shalmica R.

AU - Dikmen, Z. Gunnur

AU - Wright, Woodring E.

AU - Shay, Jerry W.

N1 - Funding Information: This work was supported by Lung SPORE CA70907 and the Nash Foundation. We thank Stanton Fernald for the illustrations.

PY - 2005

Y1 - 2005

N2 - Advances in chromosome dynamics have increased our understanding of the significant role of telomeres and telomerase in cancer. Telomerase is expressed in almost all cancer cells but is inactive in most normal somatic cells. Therefore, telomerase is an important target for the design of therapeutic agents that might have minimal side effects. Herein, we evaluate current approaches to telomerase-targeted therapy, discuss the benefits and disadvantages, and speculate on the future direction of telomerase inhibitors as cancer therapeutics.

AB - Advances in chromosome dynamics have increased our understanding of the significant role of telomeres and telomerase in cancer. Telomerase is expressed in almost all cancer cells but is inactive in most normal somatic cells. Therefore, telomerase is an important target for the design of therapeutic agents that might have minimal side effects. Herein, we evaluate current approaches to telomerase-targeted therapy, discuss the benefits and disadvantages, and speculate on the future direction of telomerase inhibitors as cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=33645089672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645089672&partnerID=8YFLogxK

U2 - 10.1016/j.ddmec.2005.05.009

DO - 10.1016/j.ddmec.2005.05.009

M3 - Review article

AN - SCOPUS:33645089672

SN - 1740-6765

VL - 2

SP - 159

EP - 164

JO - Drug Discovery Today: Disease Mechanisms

JF - Drug Discovery Today: Disease Mechanisms

IS - 2

ER -

Telomerase as a therapeutic target in cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this